| Literature DB >> 21552561 |
Cristian Koepfli1, Sonja Schoepflin, Michael Bretscher, Enmoore Lin, Benson Kiniboro, Peter A Zimmerman, Peter Siba, Thomas A Smith, Ivo Mueller, Ingrid Felger.
Abstract
BACKGROUND: In malaria endemic areas, most people are simultaneously infected with different parasite clones. Detection of individual clones is hampered when their densities fluctuate around the detection limit and, in case of P. falciparum, by sequestration during part of their life cycle. This has important implications for measures of levels of infection or for the outcome of clinical trials. This study aimed at measuring the detectability of individual P. falciparum and P. vivax parasite clones in consecutive samples of the same patient and at investigating the impact of sampling strategies on basic epidemiological measures such as multiplicity of infection (MOI).Entities:
Mesh:
Year: 2011 PMID: 21552561 PMCID: PMC3084249 DOI: 10.1371/journal.pone.0019010
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Dynamics of parasite clones over 24 hours.
Schematic overview of possible outcomes of 24 h bleeds. A sample is positive as soon as a parasite is detected on either day. Different colors of PCR results indicate different clones detected. The combined multiplicity of infection includes all clones detected in two corresponding bleeds.
Effect of repeated sampling on P. falciparum and P. vivax prevalence by light microscopy or PCR.
|
|
|
|
|
|
| |
| Microscopy |
| Microscopy |
| MS16 PCR | PCR 2 markers | |
|
| ||||||
| 1st day pos., 2nd day neg. | 39 (16.1%) | 21 (6.8%) | 57 (10.1%) | 39 (6.3%) | 49 (7.8%) | 40 (6.1%) |
| 1st day neg., 2nd day pos. | 47 (19.4%) | 28 (9.0%) | 68 (12.1%) | 56 (9.1%) | 58 (9.1%) | 55 (8.4%) |
| Both days positive | 156 (64.5%) | 262 (84.2%) | 438 (77.8%) | 521 (84.6%) | 527 (83.1%) | 557 (85.5%) |
|
|
|
|
|
|
|
|
|
| ||||||
| Prevalence on 1st day (n = 1019 samples) | 0.19 (195/1019) | 0.29 (283/1019) | 0.49 (495/1019) | 0.55 (560/1019) | 0.57 (576/1019) | 0.59 (597/1019) |
| Prevalence on 2nd day (n = 1019 samples) | 0.20 (203/1019) | 0.28 (290/1019) | 0.50 (506/1019) | 0.57 (577/1019) | 0.57 (585/1019) | 0.60 (612/1019) |
| Prevalence 2 days combined (n = 1019 pairs) | 0.24 (242/1019) | 0.31(311/1019) | 0.55 (563/1019) | 0.60 (616/1019) | 0.62 (634/1019) | 0.64 (652/1019) |
|
| 0.78 [0.74–0.83] | 0.91 [0.89–0.94] | 0.88 [0.86–0.89] | 0.92 [0.90–0.93] | 0.91 [0.89–0.93] | 0.92 [0.91–0.94] |
A sample was defined positive for P. vivax if any of the two markers msp1F3 or MS16 was amplified.
These samples are positive on day 1 for at least one marker and negative on day 2 for both markers.
These samples are negative on day 1 for both markers and positive on day 2 for at least one marker.
Detectability refers to PCR positivity at day 1 versus day 2.
Effect of repeated sampling on molecular detection of parasite clones and on multiplicity of infection.
|
|
|
|
| |
|
|
| MS16 | 2 markers combined | |
|
| ||||
| No. clones detected only on day 1 | 93 (18.0%) | 382 (23.8%) | 495 (25.2%) | |
| No. clones detected only on day 2 | 90 (17.4%) | 307 (19.2%) | 617 (31.3%) | |
| No. clones detected on both days | 335 (64.7%) | 912 (57.0%) | 855 (43.5%) | |
|
|
|
|
| |
|
| 0.79 [0.76–0.82] | 0.73 [0.71–0.75] | 0.61 [0.58–0.63] | |
|
| ||||
| MOI on day 1 | 1.53 | 2.31 | 2.34 | 2.78 |
| MOI on day 2 | 1.47 | 2.11 | 2.52 | 2.77 |
| MOI on both days | 1.68 | 2.60 | 3.10 | 3.37 |
The highest value for MOI of either marker msp1F3 or MS16 was used.
Detectability refers to individual genotypes at day 1 versus day 2.
Figure 2Examples of results obtained on two consecutive days by PCR-capillary electrophoresis.
Capillary electrophoresis chromatograms obtained with the P. vivax marker msp1F3 from two patients on two consecutive days. X-axis: size of PCR product in base pairs. Y-axis: relative fluorescent units. In patient 1 one clone was detected on day 1, and two additional clones were detected on day 2, combined MOI = 3. Patient 2 was negative on day 1, but one clone was found on day 2, combined MOI = 1.
Figure 3Detectablity of Plasmodium infections and parasite clones in different age groups.
Values for microscopy and “P. vivax PCR any marker” refer to detection of parasites without distinction of clones. Values for the molecular markers P. falciparum msp2, P. vivax msp1F3 and P. vivax MS16 refer to the detection of parasite clones. Larger 95% CI of P. falciparum detectability are mainly caused by smaller sample size.
Figure 4Detectablity of parasite clones vs. multiplicity of infection.
Figure 5Detectablity of parasite clones in patients harbouring different parasite densities.